Effect of valproic acid treatment on copper availability in adult epileptic patients

Clinical Biochemistry

Volumn 43, Issue 13-14, 2010, Pages 1074-1078

  Lampón, Natalia ^a   Tutor, J Carlos ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Ceruloplasmin specific oxidase activity; Copper status; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; CERULOPLASMIN; COPPER; OXIDOREDUCTASE; VALPROIC ACID;

ADULT; ANALYTICAL EQUIPMENT; ANALYZER; ANTICONVULSANT THERAPY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BILIARY EXCRETION; CONTROLLED STUDY; COPPER METABOLISM; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; PRIORITY JOURNAL; SERUM;

ADULT; ANTICONVULSANTS; CASE-CONTROL STUDIES; CERULOPLASMIN; COPPER; EPILEPSY; HUMANS; VALPROIC ACID;

EID: 77956177562     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.06.016     Document Type: Article

References (36)

1. Pekary A.E., Stevens S.A., Sattin A. Valproate and copper accelerate TRH-like peptide synthesis in male rat pancreas and reproductive tissues. Peptides 2006, 27:2901-2911.
2. Roberts E.A., Sarkar B. Liver as key organ in the supply, storage, and excretion of copper. Am. J. Clin. Nutr. 2008, 88:851S-854S. Suppl.
3. Watkins J.B., Klaassen C.D. Choleretic effect of valproic acid in the rat. Hepatology 1981, 1:341-347.
4. Kuzuya T., Amioka K., Nabeshima T. Valproic acid increases biliary copper excretion in the rat. Epilepsy Res. 2002, 51:279-285.
5. Kaji M., Ito M., Okuno T., Momoi T., Sasaki H., Yamanaka C., Yorifuji T., Mikawa H. Serum copper and zinc levels in epileptic children with valproate treatment. Epilepsia 1992, 33:555-557.
6. Verrotti A., Basciani F., Trotta D., Pomilio M.P., Morgese G., Chiarelli F. Serum copper, zinc selenium, glutathione peroxidase, and superoxide dismutase levels in epileptic children before and after 1year of sodium valproate and carbamazepine therapy. Epilepsy Res. 2002, 48:71-75.
7. Kurecki A.E., Alpay F., Tanindi S., Gokcay E., Ozcan O., Akin R., Isimer A., Sayal A. Plasma trace element, plasma glutathione peroxidise, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. Epilepsia 1995, 36:600-604.
8. Kuzuya T., Hasegawa T., Shimizu K., Nabeshima T. Effect of antiepileptic drug on serum zinc and copper concentrations in epileptic patients. Int. J. Clin. Pharmacol. 1993, 31:61-65.
9. Geubel A.P., Gregoire V., Rahier J., Lissens W., Dive C. Hypoceruloplasminemia and ultrastructural changes resembling Wilson' s disease in non-alcoholic liver steatosis. A clinical and pathological study of five cases. Liver 1988, 8:299-306.
10. Ferenci P., Steindl-Munda P., Vogel W., Jessner W., Gschwantler M., Stauber R., et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's disease. Clin. Gastroenterol. Hepatol. 2005, 3:811-818.
11. Aigner E., Theurl I., Haufe H., Seifert M., Hohla F., Scharingre L., et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterol 2008, 135:680-688.
12. Luef G.J., Waldmann M., Sturm W., Naser A., Trinka E., Unterberger I., et al. Valproate therapy and non-alcoholic fatty liver disease. Ann. Neurol. 2004, 55:729-732.
13. Luef G., Rauchenzauner M., Waldmann M., Strun W., Sandhofer A., Seppi K., et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009, 86:42-47.
14. Tutor-Crespo M.J., Hermida J., Tutor J.C. Assessment of copper status in epileptic patients treated with anticonvulsant drugs by measuring the specific oxidase activity of ceruloplasmin. Epilepsy Res. 2003, 56:147-153.
15. Hambidge M. Biomarkers of trace mineral intake and status. J. Nutr. 2003, 133(Suppl 3):948S-955S.
16. Milne D.B. Assessment of copper nutritional status. Clin. Chem. 1994, 40:1479-1484.
17. Milne D.B. Copper intake and assessment of copper status. Am. J. Clin. Nutr. 1998, Suppl 67:1041S-1045S.
18. Louro M.O., Tutor J.C. Assessment of copper status in pregnant women. Eastern J Med 2003, 8:46-47.
19. Walshe J.M. Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann. Clin. Biochem. 2003, 40:115-121.
20. Louro M.O., Cocho J.A., Tutor J.C. Assessment of copper status in pregnancy by means of determining the specific oxidase activity of ceruloplasmin. Clin. Chim. Acta 2001, 312:123-127.
21. Milne D.B., Johnson P.E. Assessment of copper status: effect of age and gender on reference ranges in healthy adults. Clin. Chem. 1993, 39:883-887.
22. Milne D.B. Trace elements. Tietz Fundamentals of Clinical Chemistry 2001, 568-583. W.B. Saunders Company, Philadelphia. Fifth Edition.
23. Beetham R. Use of serum copper to caeruloplasmin ratio to highlight relative copper excess in Wilson's disease. Ann. Clin. Biochem. 2006, 43:53. Suppl.
24. Twomey P.J., Viljoen A., House I.M., Reynolds T.M., Wierzbicki A.S. Copper: ceruloplasmin ratio. J. Clin. Pathol. 2007, 60:441-442.
25. Louro M.O., Tutor J.C. Determinación de la actividad oxidásica de la ceruloplasmina en los analizadores Cobas Bio y Cobas Fara. Acta Bioquim. Clin. Latinoam. 1991, 25:119-125.
26. Hermida J., Tutor J.C. A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients. J. Pharmacol. Sci. 2005, 97:489-493.
27. Tutor J.C., Fernández M.P., Paz J.M. Serum copper concentration and hepatic enzyme induction during long-term therapy with anticonvulsants. Clin. Chem. 1982, 28:1367-1370.
28. AHA/CDC scientific statement on markers of inflammation and cardiovascular disease. Circulation 2003; 107: 499-511.
29. Mintzer S., Skidmore C.T., Abidin C.J., Morales M.C., Chervoneva I., Capuzzi D.M., et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann. Neurol. 2009, 65:448-456.
30. Tan T.Y., Lu C.H., Chuang H.Y., Lin T.K., Liou C.W., Chang W.N., et al. Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 2009, 50:1579-1586.
31. Hellman N.E., Gitlin J.D. Ceruloplasmin metabolism and function. Annu. Rev. Nutr. 2002, 22:439-458.
32. Macintyre G., Gutefreund K.S., Martin W.R.W., Camicioli R., Cox D.W. Value of an enzymatic assay for the determination of serum ceruloplasmin. J. Lab. Clin. Med. 2004, 144:294-301.
33. Quinn J.F., Crane S., Harris C., Wasdsworth T.L. Copper in Alzheimer's disease: too much or to little?. Expert Rev. Neurother. 2009, 9:631-637.
34. Zhang X.Z., Li X.J., Zhang H.Y. Valproic acid as a promising agent to combat Alzheimer's disease. Brain Res. Bull. 2010, 81:3-6.
35. Choi B.S., Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res. 2009, 1248:14-21.
36. Uhlikova E., Kupcova V., Szantova M., Turecky L. Plasma copper and ceruloplasmin in patients with alcoholic liver steatosis. Bratisl. Lek. Listy 2008, 109:431-433.